PYXS · Pyxis Oncology Inc
United States · RS rating 21 · As of 2026-11-03
| Price | 1.64 USD |
|---|---|
| 1-day change | -3.0% |
| RS rating (overall / 1M / 3M / 12M) | 21 / 15 / 10 / 20 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 24 / 30 / 18 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -8.1% |
| Sales growth Q/Q | -100.0% |
| Distance from 52-week high | +69.3% |
| Market cap (USD) | $107.4M |